A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic RCC who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting.
Inclusion Criteria:
Exclusion Criteria:
Disease-Specific Exclusions:
General Medical Exclusions:
Exclusion Criteria Related to Medications:
Bevacizumab- and Sunitinib-Specific Exclusions:
Orange, California 92868, United States
Praha 4 - Krc, 140 59, Czechia
Heidelberg, 69120, Germany
Meldola, Emilia-Romagna 47014, Italy
Milan, Lombardy 20162, Italy
Gunma, 371-8511, Japan
Hokkaido, 060-8648, Japan
Poznan, 60-569, Poland
Nizhny Novgorod, Niznij Novgorod 603001, Russia
Edirne, 22770, Turkey (Türkiye)